Northwestern Medicine scientists have recently discovered that two common genetic risk factors for Parkinson’s disease can be regulated with LRRK2 kinase inhibition or GCase enzyme activation, revealing potential for the development of new therapeutics.
People who carry genetic mutations associated with an increased risk for Parkinson’s disease may exhibit minor symptoms long before the disease progresses to affect daily life, according to a study of over 300 patients.
According to a recent study, elevated ocular pressure in glaucoma is generated in the wall of a small vessel in the eye, the Schlemm’s canal.
An AI model predicted breast cancer in mammograms more accurately than radiologists, reducing false positives and false negatives, according to a new study.
A new lipid nanoparticle drug helped make tumor cells more vulnerable to therapy, significantly prolonging survival in models of glioblastoma.
Scientists have discovered why a specific genetic mutation causes intellectual disability and autism spectrum disorder in children.
A cancer drug that washed out of clinical trials more than 15 years ago may be the key to slowing the progression of Parkinson’s disease, according to a Northwestern Medicine study.
Northwestern Medicine scientists have developed a new strategy to treat Parkinson’s disease by mitigating the effects of harmful genetic mutations, according to a recent study.
This article was originally published in the Breakthroughs Newsletter. Find more stories like this, as…
Boosting the activity of newly-created neurons mimicked the effect of antidepressant medication in mouse models, according to a recent study.